Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Artru

Showing results (21-30 of 83) with videos related to

Pageof 9
Sort By:
Gastroenterologie Clinique Et Biologique|August 24, 2002
[5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer]Julien Taïeb, Thierry Lecomte, Joël Ezenfis, et al.
Cancer|April 17, 2008
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 studyAmani Asnacios, Laetitia Fartoux, Olivier Romano, et al.
Gastroenterologie Clinique Et Biologique|March 2, 2005
Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patientsLaetitia Dahan, Dan Atlan, Olivier Bouché, et al.
Endoscopic Ultrasound|December 20, 2022
Efficacy of EUS-guided hepaticogastrostomy in prolonging survival of patients with perihilar cholangiocarcinomaArmelle Schoch, Andrea Lisotti, Thomas Walter, et al.
Cancer Management and Research|October 6, 2018
Computed tomography scan efficacy in staging gastric linitis plastica lesion: a retrospective multicentric French studyStéphanie Morgant, Pascal Artru, Ammar Oudjit, et al.
Clinical Colorectal Cancer|November 28, 2021
Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II StudyAurelie Bertaut, Yann Touchefeu, Julie Blanc, et al.
BMC Cancer|May 31, 2020
NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)Antoine Brouquet, Jean-Baptiste Bachet, Florence Huguet, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2019
Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre studyClaire Gallois, Pascal Artru, Astrid Lièvre, et al.
Clinics and Research in Hepatology and Gastroenterology|March 4, 2021
Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter studyClaire Gallois, Camille Bourillon, Edouard Auclin, et al.
The Oncologist|August 24, 2011
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR studyBenoist Chibaudel, Franck Bonnetain, Christophe Tournigand, et al.
Pageof 9

Showing results (21-30 of 83) with videos related to

Sort By:
Pageof 9
Gastroenterologie Clinique Et Biologique|August 24, 2002
[5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer]Julien Taïeb, Thierry Lecomte, Joël Ezenfis, et al.
Cancer|April 17, 2008
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 studyAmani Asnacios, Laetitia Fartoux, Olivier Romano, et al.
Gastroenterologie Clinique Et Biologique|March 2, 2005
Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patientsLaetitia Dahan, Dan Atlan, Olivier Bouché, et al.
Endoscopic Ultrasound|December 20, 2022
Efficacy of EUS-guided hepaticogastrostomy in prolonging survival of patients with perihilar cholangiocarcinomaArmelle Schoch, Andrea Lisotti, Thomas Walter, et al.
Cancer Management and Research|October 6, 2018
Computed tomography scan efficacy in staging gastric linitis plastica lesion: a retrospective multicentric French studyStéphanie Morgant, Pascal Artru, Ammar Oudjit, et al.
Clinical Colorectal Cancer|November 28, 2021
Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II StudyAurelie Bertaut, Yann Touchefeu, Julie Blanc, et al.
BMC Cancer|May 31, 2020
NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)Antoine Brouquet, Jean-Baptiste Bachet, Florence Huguet, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2019
Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre studyClaire Gallois, Pascal Artru, Astrid Lièvre, et al.
Clinics and Research in Hepatology and Gastroenterology|March 4, 2021
Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter studyClaire Gallois, Camille Bourillon, Edouard Auclin, et al.
The Oncologist|August 24, 2011
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR studyBenoist Chibaudel, Franck Bonnetain, Christophe Tournigand, et al.
Pageof 9